Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Phase 2
100
about 2.7 years
18+
1 site in PA
About this study
Researchers are testing whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome. This treatment is being used in adults who have lymphoma or multiple myeloma and are undergoing autologous stem cell transplantation. The trial will last for about 988 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Gcsf
- 2.Take Plerixafor
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
colony stimulating factor, plerixafor
injection, subcutaneous
Secondary: Cytokine Analysis, Disease Response, Length of Hospital Stay
Oncology